Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jason W. Boggs
Observed names:
Boggs, Jason,
J. Boggs,
Jason Boggs
Institution:
Genentech
Observed institutions:
Oslo University Hospital,
University of Minnesota,
Genentech,
Czech Academy of Sciences,
WuXi AppTec (China),
Czech Academy of Sciences, Institute of Molecular Genetics,
Evotec (United Kingdom),
Pharmaron (China),
University of California, Berkeley
show all 9
OpenAlex ID:
A5047816882
A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth
2013
·
Ted Lau
, Emily Chan
, et al.
·
Cancer Research
·
347
Tankyrase Inhibition Causes Reversible Intestinal Toxicity in Mice with a Therapeutic Index < 1
2015
·
Yu Zhong
, Paula Katavolos
, et al.
·
Toxicologic Pathology
·
113
PDF
Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton’s Tyrosine Kinase Inhibitor
2011
·
Lichuan Liu
, Jason S. Halladay
, et al.
·
Drug Metabolism and Disposition
·
76
Back Pocket Flexibility Provides Group II p21-Activated Kinase (PAK) Selectivity for Type I 1/2 Kinase Inhibitors
2014
·
Steven T. Staben
, Jianwen A. Feng
, et al.
·
Journal of Medicinal Chemistry
·
72
The Role of Lymphatic Transport on the Systemic Bioavailability of the Bcl-2 Protein Family Inhibitors Navitoclax (ABT-263) and ABT-199
2013
·
Edna F Choo
, Jason Boggs
, et al.
·
Drug Metabolism and Disposition
·
66
Evaluation of geranylazide and farnesylazide diphosphate for incorporation of prenylazides into a CAAX box‐containing peptide using protein farnesyltransferase*
2005
·
M.W. Rose
, N.D. Rose
, et al.
·
Journal of Peptide Research
·
57
PDF
Discovery of Selective 4-Amino-pyridopyrimidine Inhibitors of MAP4K4 Using Fragment-Based Lead Identification and Optimization
2014
·
Terry D. Crawford
, Chudi O. Ndubaku
, et al.
·
Journal of Medicinal Chemistry
·
52
Potent and Selective Aminopyrimidine-Based B-Raf Inhibitors with Favorable Physicochemical and Pharmacokinetic Properties
2012
·
Simon Mathieu
, Stefan N. Gradl
, et al.
·
Journal of Medicinal Chemistry
·
51
Structure-Based Design of GNE-495, a Potent and Selective MAP4K4 Inhibitor with Efficacy in Retinal Angiogenesis
2015
·
Chudi O. Ndubaku
, Terry D. Crawford
, et al.
·
ACS Medicinal Chemistry Letters
·
50
Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase
2014
·
Peter S. Dragovich
, Benjamin P. Fauber
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
50
Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479
2014
·
Kirk D. Robarge
, Wendy Lee
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
46
PDF
Discovery of Novel Allosteric Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors Possessing Bidentate Ser212 Interactions
2012
·
Robert A. Heald
, Philip Jackson
, et al.
·
Journal of Medicinal Chemistry
·
43
Preclinical Disposition of GDC-0973 and Prospective and Retrospective Analysis of Human Dose and Efficacy Predictions
2012
·
Edna F. Choo
, Marcia Belvin
, et al.
·
Drug Metabolism and Disposition
·
34
Fragment-based identification and optimization of a class of potent pyrrolo[2,1-f][1,2,4]triazine MAP4K4 inhibitors
2014
·
Lan Wang
, Mark Stanley
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
31
PDF
Optimization of 5-(2,6-dichlorophenyl)-3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase
2014
·
Sharada Labadie
, Peter S. Dragovich
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
24
PDF
Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor
2010
·
Edna F. Choo
, Marcia Belvin
, et al.
·
Xenobiotica
·
22
An Algorithm for Evaluating Potential Tissue Drug Distribution in Toxicology Studies from Readily Available Pharmacokinetic Parameters
2013
·
Patrick Poulin
, Donna M. Dambach
, et al.
·
Journal of Pharmaceutical Sciences
·
13
Systemic in vitro and in vivo evaluation for determining the feasibility of making an amorphous solid dispersion of a B-Raf (rapidly accelerated fibrosarcoma) inhibitor
2013
·
Yong Cui
, Po-Chang Chiang
, et al.
·
International Journal of Pharmaceutics
·
13
Absorption, metabolism and excretion of cobimetinib, an oral MEK inhibitor, in rats and dogs
2016
·
Ryan H. Takahashi
, Shuguang Ma
, et al.
·
Xenobiotica
·
8
Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process
2011
·
Edna F Choo
, Bruno Alicke
, et al.
·
Xenobiotica
·
6
Assessment of the Hepatic CYP Reductase Null Mouse Model and Its Potential Application in Drug Discovery
2014
·
Jason W. Boggs
, Cornelis E. C. A. Hop
, et al.
·
Molecular Pharmaceutics
·
4
502 Preclinical Pharmacokinetics and Efficacy Assessment of a Potent and Selective MEK Inhibitor, GDC-0623
2012
·
E. Choo
, M. Belvin
, et al.
·
European Journal of Cancer
·
3
Supplementary Table 3 from A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth
2023
·
Ted Lau
, Emily Chan
, et al.
PDF
Supplementary Table S2 from A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth
2023
·
Ted Lau
, Emily Chan
, et al.
Supplementary Data from A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth
2023
·
Ted Lau
, Emily Chan
, et al.
Show more works
View as search
Works count:
37
Citation count:
1,181
H-index:
16
I10-index:
18
Year
Topic
Type